Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
The group is keeping faith with the novel target KLK2.
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.